---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307935"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:22:36.332104+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Madrigal Phase 3 MAESTRO-NASH meets dual primary endpoints; NDA planned H1 2023

## Summary
- NASH resolution endpoint met: 30% on 100mg vs 10% placebo (p<0.0001); fibrosis improvement: 26% vs 14% (p=0.0002).
- LDL-C lowering at 24 weeks: -16% on 100mg vs -1% placebo (p<0.0001); both doses statistically significant.
- Safety similar across arms: SAEs 11.8-12.7%; discontinuation low (2.8-7.7%); common AEs mild diarrhea and nausea.
- Company plans to file NDA for accelerated approval (Subpart H) in first half of 2023.

## SEC filing metadata
- accession: 0001193125-22-307935
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312522307935/0001193125-22-307935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312522307935/d423141d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307935
- JSON: https://secwatch.observer/filing/0001193125-22-307935.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.